European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 744-748 , December 2009

Prevention of strongyloides hyperinfection syndrome: A rheumatological point of view

  • Mittermayer Santiago

      Affiliations

    • Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil
    • Serviço de Reumatologia do Hospital Santa Izabel (HSI), Salvador, Bahia, Brazil
    • Corresponding Author InformationCorresponding author. Serviço de Reumatologia do Hospital Santa Izabel. Praça Almeida Couto, 500, Nazaré, Salvador, Bahia, CEP 40.050-410, Brazil. Tel.: +71 33265276.
    • ,
  • Bruno Leitão

      Affiliations

    • Serviço de Reumatologia do Hospital Santa Izabel (HSI), Salvador, Bahia, Brazil

Received 29 December 2008 ,Revised 30 August 2009 ,Accepted 4 September 2009.

References 

  1. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. Dec 2007;41(12):1992–2001
  2. Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol. Jun 2007;13(3):150–152
  3. Arthur RP, Shelley WB. Larva currens; a distinctive variant of cutaneous larva migrans due to Strongyloides stercoralis. AMA Arch Derm. Aug 1958;78(2):186–190
  4. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. Jan 2004;17(1):208–217
  5. Fardet L, Genereau T, Poirot J, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients. J Infect. 2007;54(10):18–27
  6. van Doorn HR, Koelewijn R, Hofwegen H, Gilis H, Wetsteyn JC, Wismans PJ, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol. Feb 2007;45(2):438–442
  7. Portugal R, Schaffel R, Almeida L, Spector N, Nucci M. Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: a randomized double-blind placebo-controlled study. Haematologica. Jun 2002;87(6):663–664
  8. Leang B, Lynen L, Schrooten W, Hines J. Comparison of albendazole regimen for prophylaxis of strongyloides hyperinfection in nephrotic syndrome patients on long-term steroids in Cambodia. Trop Doct. Oct 2005;35(4):212–213
  9. Archibald LK, Beeching NJ, Gill GV, Bailey JW, Bell DR. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med. Mar 1993;86(3):191–195
  10. Torres JR, Isturiz R, Murillo J, Guzman M, Contreras R. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis. Nov 1993;17(5):900–902
  11. Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, Biligui S, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg. May 1994;88(3):344–345
  12. Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis. May 1994;169(5):1076–1079
  13. Pitisuttithum P, Supanaranond W, Chindanond D. A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. Southeast Asian J Trop Med Public Health. Dec 1995;26(4):735–738
  14. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg. Nov 1996;55(5):477–481
  15. Toma H, Sato Y, Shiroma Y, Kobayashi J, Shimabukuro I, Takara M. Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan. Southeast Asian J Trop Med Public Health. Mar 2000;31(1):147–151
  16. Zaha O, Hirata T, Kinjo F, Saito A, Fukuhara H. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2weeks apart. J Infect Chemother. Mar 2002;8(1):94–98
  17. Zaha O, Hirata T, Uchima N, Kinjo F, Saito A. Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother. Dec 2004;10(6):348–351
  18. Igual-Adell R, Oltra-Alcaraz C Soler-Company, Sanchez-Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. Dec 2004;5(12):2615–2619
  19. Nontasut P, Muennoo C, Sa-nguankiat S, Fongsri S, Vichit A. Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole. Southeast Asian J Trop Med Public Health. Mar 2005;36(2):442–444
  20. Singthong S, Intapan PM, Wongsaroji T, Maleewong W. Randomized comparative trial of two high-dose albendazole regimens for uncomplicated human strongyloidiasis. Southeast Asian J Trop Med Public Health. 2006;37(Suppl 3):32–34
  21. Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents. Jan 2008;31(1):46–49
  22. Nucci M, Portugal R, Pulcheri W, Spector N, Ferreira SB, de Castro MB, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis. Sep 1995;21(3):675–677
  23. Rao PN, Kiran KU. Preventing strongyloidiasis in the immunosuppressed. Indian J Dermatol Venereol Leprol. Sep 2005;71(5):363–364
  24. Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis. A case–control study. Arch Intern Med. Feb 1984;144(2):321–324
  25. Fardet L, Genereau T, Cabane J, Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect. Oct 2006;12(10):945–947
  26. Moreira ED, Ribeiro TT, Swanson P, Sampaio FC, Melo A, Brites C, et al. Seroepidemiology of human T-cell lymphotropic virus type I/II in northeastern Brazil. J Acquir Immune Defic Syndr. Aug 1993;6(8):959–963
  27. Hirata T, Uchima N, Kishimoto K, Zaha O, Kinjo N, Hokama A, et al. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg. Feb 2006;74(2):246–249
  28. Zaha O, Hirata T, Kinjo F, Saito A. Strongyloidiasis—progress in diagnosis and treatment. Intern Med. Sep 2000;39(9):695–700
  29. Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg. Apr 2008;102(4):314–318
  30. Vassilopoulos D, Calabrese LH. Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Cleve Clin J Med. Sep 1998;65(8):436–441
  31. Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis. Mar 2002;6(1):28–30
  32. Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg. Nov 2007;101(11):1163–1165
  33. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. Oct 1 2001;33(7):1040–1047
  34. Ainley CC, Clarke DG, Timothy AR, Thompson RP. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut. Mar 1986;27(3):337–338
  35. Davis JS, Currie BJ, Fisher DA, Huffam SE, Anstey NM, Price RN, et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell. 2003;27(4):526–532
  36. Greene BM, Dukuly ZD, Munoz B, White AT, Pacque M, Taylor HR. A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis. Feb 1991;163(2):376–380
  37. Page WA, Dempsey K, McCarthy JS. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans R Soc Trop Med Hyg. Nov 2006;100(11):1056–1062
  38. Schaffel R, Nucci M, Carvalho E, Braga M, Almeida L, Portugal R, et al. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am J Trop Med Hyg. Oct 2001;65(4):346–350
  39. Kobayashi J, Sato Y, Toma H, Takara M, Shiroma Y. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis. Jan 1994;18(1):19–23

PII: S0953-6205(09)00168-X

doi: 10.1016/j.ejim.2009.09.001

European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 744-748 , December 2009

Article Tools